Arbutus Biopharma Corp (ABUS) Stock: The Story of a 52-Week Stock Range

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Arbutus Biopharma Corp’s current trading price is -19.24% away from its 52-week high, while its distance from the 52-week low is 50.30%. The stock’s price range for this period has been between $1.69 and $3.14 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 4.33 million for the day, a number notably higher than the average daily volume of 0.79 million over the last three months.

Arbutus Biopharma Corp ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $3.14 on 03/30/23, while the lowest value for the same period was recorded at $1.69 on 10/24/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis

Arbutus Biopharma Corp (ABUS) has experienced a quarterly rise of 37.30% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 425.93M and boasts a workforce of 98 employees.

Analyzing Trading Volume and Moving Average Trends

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.08, with a change in price of +0.50. Similarly, Arbutus Biopharma Corp recorded 744,072 in trading volume during the last 100 days, posting a change of +24.51%.

Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis

The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ABUS stands at 0.08. Similarly, the long-term debt-to-equity ratio is also 0.08.

ABUS Stock Stochastic Average

Arbutus Biopharma Corp’s raw stochastic average for the past 50 days is presently 87.21%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 75.00%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 77.94% and 66.63%, respectively.

ABUS Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Year to date metric has recorded a gain of 1.60%.However, over the last six months, we can see a weaker performance of 25.12%. Over the last 30 days, the price of ABUS has fallen by 4.53%. And in the last five days, it has surged by 5.83%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts